Iron deficiency in pulmonary arterial hypertension: A potential therapeutic target

European Respiratory Journal

Volumn 38, Issue 6, 2011, Pages 1453-1460

  Rhodes, C J ^a   Wharton, J ^a   Howard, L ^a   Gibbs, J S R ^a   Vonk Noordegraaf, A ^b   Wilkins, M R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Heart failure; Hypoxia; Iron; Pulmonary arterial hypertension; Pulmonary vascular resistance; Pulmonary vasculature

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2; FERRIC CARBOXYMALTOSE; FERRITIN; HEPCIDIN; PLACEBO;

ANEMIA; BLOOD VESSEL REACTIVITY; CHRONIC DISEASE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG TARGETING; EXERCISE; HEART FAILURE; HEART FUNCTION; HEREDITY; HOMEOSTASIS; HUMAN; HYPOXIA; INFLAMMATION; INTRACELLULAR SIGNALING; IRON DEFICIENCY ANEMIA; IRON INTAKE; IRON THERAPY; LUNG CIRCULATION; LUNG VASOCONSTRICTION; MUSCLE FUNCTION; NONHUMAN; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; REVIEW; SKELETAL MUSCLE; SURVIVAL RATE; TREATMENT RESPONSE;

ANIMALS; ANOXIA; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; IRON; LUNG; MALE; MICE; RATS;

EID: 79957975690     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00037711     Document Type: Review

References (81)

1. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010; 121: 2045-2066.
2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54.
3. Ruiter G, Lankhorst S, Boonstra A, et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J 2011; 37: 1386-1391.
4. Soon E, Treacy CM, Toshner MR, et al. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax 2011; 66: 326-332.
5. Rhodes CJ, Howard LS, Busbridge M, et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes and mechanistic insights. J Am Coll Cardiol 2011; 58: 300-309.
6. Ivan M, Kondo K, Yang H, et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292: 464-468. (Pubitemid 32335941)
7. 2-regulated prolyl hydroxylation. Science 2001; 292: 468-472.
8. Balanos GM, Dorrington KL, Robbins PA. Desferrioxamine elevates pulmonary vascular resistance in humans: potential for involvement of HIF-1. J Appl Physiol 2002; 92: 2501-2507. (Pubitemid 34666376)
9. Smith TG, Balanos GM, Croft QP, et al. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol 2008; 586: 5999-6005.
10. Smith TG, Talbot NP, Privat C, et al. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. JAMA 2009; 302: 1444-1450.
11. Joyner MJ, Johnson BD. Iron lung? New ideas about hypoxic pulmonary vasoconstriction. J Physiol 2008; 586: 5837-5838.
12. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 955-962. (Pubitemid 32912694)
13. Horwich TB, Fonarow GC, Hamilton MA, et al. Anaemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002; 39: 1780-1786. (Pubitemid 34595288)
14. Mozaffarian D, Nye R, Levy WC. Anaemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 2003; 41: 1933-1939. (Pubitemid 36677110)
15. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31: 1872-1880.
16. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anaemia in patients with chronic heart failure. J Am Coll Cardiol 2006; 48: 1225-1227. (Pubitemid 44345150)
17. Toblli JE, Lombrana A, Duarte P, et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007; 50: 1657-1665. (Pubitemid 47562670)
18. Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency: FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51: 103-112.
19. Usmanov RI, Zueva EB, Silverberg DS, et al. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008; 21: 236-242.
20. Anker SD, Comin CJ, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448.
21. Finch CA, Miller LR, Inamdar AR, et al. Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction. J Clin Invest 1976; 58: 447-453.
22. Ohira Y, Edgerton VR, Gardner GW, et al. Work capacity, heart rate and blood lactate responses to iron treatment. Br J Haematol 1979; 41: 365-372. (Pubitemid 9109600)
23. Patel KV, Semba RD, Ferrucci L, et al. Red cell distribution width and mortality in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci 2010; 65: 258-265.
24. Forhecz Z, Gombos T, Borgulya G, et al. Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. Am Heart J 2009; 158: 659-666.
25. Hampole CV, Mehrotra AK, Thenappan T, et al. Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. Am J Cardiol 2009; 104: 868-872.
26. Krasuski RA, Hart SA, Smith B, et al. Association of anaemia and long-term survival in patients with pulmonary hypertension. Int J Cardiol 2011; 150: 291-295.
27. Nickel N, Kempf T, Tapken H, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 534-541.
28. Lakhal S, Talbot NP, Crosby A, et al. Regulation of growth differentiation factor 15 expression by intracellular iron. Blood 2009; 113: 1555-1563.
29. Weiss G, Goodnough LT. Anaemia of chronic disease. N Engl J Med 2005; 352: 1011-1023.
30. Cook JD, Dassenko S, Skikne BS. Serum transferrin receptor as an index of iron absorption. Br J Haematol 1990; 75: 603-609. (Pubitemid 20271496)
31. Huebers HA, Beguin Y, Pootrakul P, et al. Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood 1990; 75: 102-107. (Pubitemid 20031496)
32. Mainguy V, Maltais F, Saey D, et al. Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension. Thorax 2010; 65: 113-117.
33. Finch CA, Deubelbeiss K, Cook JD, et al. Ferrokinetics in man. Medicine (Baltimore) 1970; 49: 17-53.
34. Brunori M. Myoglobin strikes back. Protein Sci 2010; 19: 195-201.
35. Flogel U, Fago A, Rassaf T. Keeping the heart in balance: the functional interactions of myoglobin with nitrogen oxides. J Exp Biol 2010; 213: 2726-2733.
36. Robach P, Cairo G, Gelfi C, et al. Strong iron demand during hypoxia-induced erythropoiesis is associated with down-regulation of iron-related proteins and myoglobin in human skeletal muscle. Blood 2007; 109: 4724-4731. (Pubitemid 46827764)
37. Reynafarje B. Myoglobin content and enzymatic activity of muscle and altitude adaptation. J Appl Physiol 1962; 17: 301-305.
38. Kooyman GL, Ponganis PJ. The physiological basis of diving to depth: birds and mammals. Annu Rev Physiol 1998; 60: 19-32. (Pubitemid 28157862)
39. Kanatous SB, Garry DJ. Gene deletional strategies reveal novel physiological roles for myoglobin in striated muscle. Respir Physiol Neurobiol 2006; 151: 151-158.
40. Kanatous SB, Mammen PP, Rosenberg PB, et al. Hypoxia reprograms calcium signaling and regulates myoglobin expression. Am J Physiol Cell Physiol 2009; 296: C393-C402.
41. Bekedam MA, van Beek-Harmsen BJ, van Mechelen W, et al. Myoglobin concentration in skeletal muscle fibers of chronic heart failure patients. J Appl Physiol 2009; 107: 1138-1143.
42. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990; 186: 1-85. (Pubitemid 20279941)
43. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005; 202: 199-211. (Pubitemid 40040559)
44. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009; 122: 78-86.
45. Goumans MJ, Liu Z, Ten Dijke P. TGF-β signaling in vascular biology and dysfunction. Cell Res 2009; 19: 116-127.
46. Wang RH, Li C, Xu X, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2005; 2: 399-409.
47. Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009; 41: 482-487.
48. Meynard D, Kautz L, Darnaud V, et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 2009; 41: 478-481.
49. Niederkofler V, Salie R, Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest 2005; 115: 2180-2186. (Pubitemid 41134159)
50. Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002; 105: 1672-1678. (Pubitemid 34298611)
51. Machado RD, Eickelberg O, Elliott CG, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S32-S42.
52. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anaemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-2463. (Pubitemid 36857598)
53. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-1276. (Pubitemid 39069926)
54. Steinbicker AU, Sachidanandan C, Vonner AJ, et al. Inhibition of bone morphogenetic protein signaling attenuates anaemia associated with inflammation. Blood 2011; 117: 4915-4923.
55. Farha S, Asosingh K, Xu W, et al. Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood 2011; 117: 3485-3493.
56. Ikeda Y, Tajima S, Yoshida S, et al. Deferoxamine promotes angiogenesis via the activation of vascular endothelial cell function. Atherosclerosis 2011; 215: 339-347.
57. Benyamin B, McRae AF, Zhu G, et al. Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. Am J Hum Genet 2009; 84: 60-65.
58. Njajou OT, Alizadeh BZ, Aulchenko Y, et al. Heritability of serum iron, ferritin and transferrin saturation in a genetically isolated population, the Erasmus Rucphen Family (ERF) Study. Hum Hered 2006; 61: 222-228. (Pubitemid 44357219)
59. Whitfield JB, Cullen LM, Jazwinska EC, et al. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am J Hum Genet 2000; 66: 1246-1258. (Pubitemid 30468782)
60. Benyamin B, Ferreira MA, Willemsen G, et al. Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet 2009; 41: 1173-1175.
61. Chambers JC, Zhang W, Li Y, et al. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet 2009; 41: 1170-1172.
62. Tanaka T, Roy CN, Yao W, et al. A genome-wide association analysis of serum iron concentrations. Blood 2010; 115: 94-96.
63. Soranzo N, Spector TD, Mangino M, et al. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet 2009; 41: 1182-1190.
64. Pichler I, Minelli C, Sanna S, et al. Identification of a common variant in the TFR2 gene implicated in the physiological regulation of serum iron levels. Hum Mol Genet 2011; 20: 1232-1240.
65. Park AM, Wong CM, Jelinkova L, et al. Pulmonary hypertension-induced GATA4 activation in the right ventricle. Hypertension 2010; 56: 1145-1151.
66. Lawrie A, Spiekerkoetter E, Martinez EC, et al. Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res 2005; 97: 227-235. (Pubitemid 41105448)
67. Greenway S, van Suylen RJ, Du Marchie SG, et al. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am J Pathol 2004; 164: 253-262. (Pubitemid 38364609)
68. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108: 1141-1150. (Pubitemid 32995372)
69. B receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002; 165: 398-405.
70. Suzuki YJ, Nagase H, Wong CM, et al. Regulation of Bcl-xL expression in lung vascular smooth muscle. Am J Respir Cell Mol Biol 2007; 36: 678-687. (Pubitemid 46871422)
71. Naito Y, Hirotani S, Sawada H, et al. Dietary iron restriction prevents hypertensive cardiovascular remodeling in Dahl salt-sensitive rats. Hypertension 2011; 57: 497-504.
72. Dong F, Zhang X, Culver B, et al. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond) 2005; 109: 277-286. (Pubitemid 41337132)
73. Naito Y, Tsujino T, Matsumoto M, et al. Adaptive response of the heart to long-term anaemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 2009; 296: H585-H593.
74. Naito Y, Tsujino T, Fujimori Y, et al. Impaired expression of duodenal iron transporters in Dahl salt-sensitive heart failure rats. J Hypertens 2011; 29: 741-748.
75. Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med (Maywood) 2007; 232: 1014-1020. (Pubitemid 47358184)
76. Valenti L, Dongiovanni P, Motta BM, et al. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol 2011; 31: 683-690.
77. Ganzoni AM. [Intravenous iron-dextran. therapeutic and experimental possibilities]. Schweiz Med Wochenschr 1970; 100: 301-303.
78. McLaughlin VV, Badesch DB, Delcroix M, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S97-S107.
79. Arena R, Lavie CJ, Milani RV, et al. Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review. J Heart Lung Transplant 2010; 29: 159-173.
80. Wilkins MR, Ali O, Bradlow W, et al. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med 2010; 181: 1106-1113.
81. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 2005; 171: 1292-1297. (Pubitemid 40740738)